Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's

Global MEK Inhibitors Market, Drug Sales & Clinical Trials to 2026: USD 3 Billion Market Opportunity Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering. The advances...

RAS Targeting Therapies Market, 2031 Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...